Skip to content

Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children

Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07188779
Acronym
RADA16 for Ped
Enrollment
134
Registered
2025-09-23
Start date
2026-07-09
Completion date
2027-12-01
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

tonsillectomy, adenoidectomy, hemostasis, postop complications

Brief summary

The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will: Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.

Detailed description

This is a prospective study evaluating the impact of intraoperative RADA16 application on the postoperative course following pediatric tonsillectomy as it relates to pain, bleeding, readmission, and use of a rescue analgesic (ex., oxycodone). We propose a randomized controlled trial whereby patients undergoing tonsillectomy would either receive a standard analgesic regimen (postoperative acetaminophen and NSAIDs plus oxycodone as a supplemental analgesic) versus intraoperative RADA16 application plus a standard analgesic regimen.

Interventions

Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.

Sponsors

Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
3 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

Children aged 3-17 years undergoing tonsillectomy +/- adenoidectomy CPT codes * 42820 (Tonsillectomy and adenoidectomy; younger than age 12) * 42821 (… age 12 or over) * 42825 (Tonsillectomy; primary or secondary; younger than age 12) * 42826 (… age 12 or over) * 42830 (Adenoidectomy, primary; younger than age 12) * 42831 (… age 12 or over) * 42835 (Adenoidectomy; secondary; younger than age 12) * 42836 (… age 12 or over)

Exclusion criteria

* Children with bleeding disorders or other hematologic malignancy or taking anticoagulant medications Developmental delay affecting pain reporting Children with known allergies to RADA16 components Children with prior tonsillectomy or tonsillotomy Children undergoing tonsillectomy with concern for cancer, Children taking opioids chronically prior to surgery, Anyone pregnant women, incarcerated individuals, children unable to speak English or Spanish

Design outcomes

Primary

MeasureTime frameDescription
Postoperative painFrom enrollment to post-operative day 30.Pain assessed via the Wong Baker Faces scale. The primary outcome measure will be assessed via online survey on post-operative day one then subsequently every other day until post-operative day fifteen, with a final survey on day 30.

Secondary

MeasureTime frameDescription
Number of Participants with post-tonsillectomy hemorrhage who receive topical agentsFrom enrollment to post-operative day 30Number of Participants with post-tonsillectomy hemorrhage who receive topical agents for management of post tonsillectomy hemorrhage
Number of Participants with post-tonsillectomy hemorrhage who require a return to the operating roomFrom enrollment to post-operative day 30Number of Participants with post-tonsillectomy hemorrhage who require a return to the operating room for management of post tonsillectomy hemorrhage
Number of participants who require hospital readmission for post tonsillectomy hemorrhage managementFrom enrollment to post-operative day thirtyNumber of participants who require readmission for management of post tonsillectomy hemorrhage
Number of participants who require a rescue analgesic for management following tonsillectomy procedureFrom enrollment to post-operative day 30Number of participants who use a rescue analgesic following their tonsillectomy procedure
Days participants take to resume their regular diet post operationFrom enrollment to post-operative day 30Recording how many days it takes for participants to return to their regular diet post operation

Countries

United States

Contacts

CONTACTWayne D Hsueh, MD
wayne.hsueh@rutgers.edu973-972-4588
CONTACTGabriel Frimpong, MPH, PA
gf345@njms.rutgers.edu973-972-2309

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026